CO5280059A1 - Derivados de 2-ox-1-pirrolidina, procewo para prepararlos y sus aplicaciones - Google Patents

Derivados de 2-ox-1-pirrolidina, procewo para prepararlos y sus aplicaciones

Info

Publication number
CO5280059A1
CO5280059A1 CO01013823A CO01013823A CO5280059A1 CO 5280059 A1 CO5280059 A1 CO 5280059A1 CO 01013823 A CO01013823 A CO 01013823A CO 01013823 A CO01013823 A CO 01013823A CO 5280059 A1 CO5280059 A1 CO 5280059A1
Authority
CO
Colombia
Prior art keywords
heteroaryl
aryl
hydroxy
alkyl
heterocycloalkyl
Prior art date
Application number
CO01013823A
Other languages
English (en)
Inventor
John Surtees
Marmon Violeta
Edmond Differding
Vincent Zimmermann
Original Assignee
Ucb Farchi S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9886259&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5280059(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Farchi S A filed Critical Ucb Farchi S A
Publication of CO5280059A1 publication Critical patent/CO5280059A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Un compuesto que tiene una fórmula (A), y sales de aceptación farmacéutica del mismo, <EMI FILE="01013823_1" ID="1" IMF=JPEG >en dondeX es -CONR5R6 ó COOR7 ó -CO-R8 ó CN;R1 es hidrógeno o alquilo, arilo, heterocicloalquilo, heteroarilo, halógeno, hidroxi, amino, nitro, ciano;R2, R3, R4 son los mismos o diferentes y cada uno es independientemente hidrógeno o halógeno, hidroxi, amino, nitro, ciano, acilo, aciloxi, sulfonilo, sulfinilo, alquilamino, carboxi, éster, éter, amido, ácido sulfónico, sulfonamida, alquilsulfonilo, arilsulfonilo, alcoxicarbonilo, alquilsulfinilo, arilsulfinilo, alquiltio, ariltio, alquilo, alcoxi, oxiéster, oxiamido, arilo, arilamino, ariloxi, heterocicloalquilo, heteroarilo, vinilo;R5, R6 y R7 son los mismos o diferentes y cada uno es independientemente hidrógeno, hidroxi, alquilo, arilo, heterocicloalquilo, heteroarilo, alcoxi, ariloxi; yR8 es hidrógeno, hidroxi, tiol, halógeno, alquilo, arilo, heterocicloalquilo, heteroarilo, alquiltio, ariltio.
CO01013823A 2000-02-23 2001-02-21 Derivados de 2-ox-1-pirrolidina, procewo para prepararlos y sus aplicaciones CO5280059A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0004297.8A GB0004297D0 (en) 2000-02-23 2000-02-23 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses

Publications (1)

Publication Number Publication Date
CO5280059A1 true CO5280059A1 (es) 2003-05-30

Family

ID=9886259

Family Applications (2)

Application Number Title Priority Date Filing Date
CO01013822A CO5271667A1 (es) 2000-02-23 2001-02-21 Derivados de 2-oxo-1-pirrilidina, porceso para prepararlos y sus aplicaciones
CO01013823A CO5280059A1 (es) 2000-02-23 2001-02-21 Derivados de 2-ox-1-pirrolidina, procewo para prepararlos y sus aplicaciones

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CO01013822A CO5271667A1 (es) 2000-02-23 2001-02-21 Derivados de 2-oxo-1-pirrilidina, porceso para prepararlos y sus aplicaciones

Country Status (43)

Country Link
US (12) US6713635B2 (es)
EP (8) EP1604979A1 (es)
JP (5) JP4081275B2 (es)
KR (4) KR100720784B1 (es)
CN (5) CN1303066C (es)
AT (5) ATE282592T1 (es)
AU (5) AU2001252144C1 (es)
BE (1) BE2016C012I2 (es)
BG (4) BG65923B1 (es)
BR (2) BRPI0108664B8 (es)
CA (2) CA2401048C (es)
CO (2) CO5271667A1 (es)
CU (2) CU23293B7 (es)
CY (3) CY1105517T1 (es)
CZ (3) CZ304420B6 (es)
DE (5) DE60113514T2 (es)
DK (3) DK1265862T3 (es)
EG (1) EG24375A (es)
ES (5) ES2334998T3 (es)
FR (1) FR16C1001I2 (es)
GB (1) GB0004297D0 (es)
HK (2) HK1052695B (es)
HU (4) HU230270B1 (es)
IL (5) IL150757A0 (es)
IS (8) IS2119B (es)
LT (1) LTC1265862I2 (es)
LU (1) LU92993I2 (es)
ME (1) ME00595B (es)
MX (2) MXPA02008206A (es)
MY (4) MY139420A (es)
NL (1) NL300815I2 (es)
NO (5) NO324051B1 (es)
NZ (1) NZ520448A (es)
PL (3) PL213669B1 (es)
PT (2) PT1447399E (es)
RO (2) RO121597B1 (es)
RS (2) RS50455B (es)
RU (5) RU2355680C2 (es)
SA (2) SA01220027B1 (es)
SI (1) SI1265862T1 (es)
TW (2) TW200626545A (es)
WO (2) WO2001062726A2 (es)
ZA (2) ZA200205671B (es)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365093B2 (en) * 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
US7122682B2 (en) * 2001-08-10 2006-10-17 Ucb, S.A. Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
EP1435943B1 (en) * 2001-10-08 2007-02-14 Ucb, S.A. Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug for treating dyskinesia
DE60233884D1 (de) 2001-10-16 2009-11-12 Memory Pharmaceutical Corp 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen
WO2003094913A1 (en) * 2002-05-14 2003-11-20 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
PL377901A1 (pl) 2003-01-13 2006-02-20 Ucb, S.A. Katalizatory uwodorniania
CN1802352A (zh) * 2003-02-03 2006-07-12 特瓦制药工业有限公司 制备左乙拉西坦的方法
ES2214147B1 (es) 2003-02-28 2005-10-01 Farma-Lepori S.A. Procedimiento de obtencion de un agente antiepileptico.
US20050143445A1 (en) * 2003-03-18 2005-06-30 Parthasaradhi Reddy B. Novel crystalline forms of levetiracetam
RU2232578C1 (ru) * 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
CA2522631A1 (en) 2003-04-16 2004-11-04 Memory Pharmaceuticals Corporation 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
EP1663968A1 (en) * 2003-09-05 2006-06-07 Ranbaxy Laboratories Limited Process for the preparation of pure levetiracetam
WO2005028435A1 (en) * 2003-09-24 2005-03-31 Ucb, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives
AU2004295083B2 (en) * 2003-12-02 2010-08-19 Ucb Pharma Imidazole derivatives, processes for preparing them and their uses
AU2005251884B2 (en) * 2004-06-11 2011-03-24 Ucb Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
AP2466A (en) * 2004-06-21 2012-09-17 Warner Lambert Co Preparation of pregabalin and related compounds
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
CN101166737A (zh) * 2004-10-20 2008-04-23 记忆药物公司 磷酸二酯酶4抑制剂
CA2488325C (en) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
EP1912966A2 (en) 2005-06-01 2008-04-23 Ucb, S.A. 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
BRPI0615830A2 (pt) * 2005-09-15 2012-12-18 Ucb Pharma Sa composto, processos para a preparação de derivados de 2-oxo-pirrolidin-1-ila, para preparação dos compostos de modo substancial diastereoisomericamente puros, para a preparação de brivaracetam e para a preparação de seletracetam, e, uso de 4-substituìdo-pirrolidin-2-onas
JP2007153755A (ja) * 2005-12-01 2007-06-21 Gifu Univ プロリン類縁体
JP2009518335A (ja) * 2005-12-07 2009-05-07 ユセベ ファルマ ソシエテ アノニム ３−カルボキシ−２−オキソ−１−ピロリジン誘導体及びそれらの使用
US8338621B2 (en) 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
LV13630B (en) * 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
JP5214597B2 (ja) * 2006-06-08 2013-06-19 ユセベ ファルマ ソシエテ アノニム ピロリジノンの共結晶
ES2450070T5 (es) 2006-06-15 2018-05-08 Ucb Pharma Gmbh Composición farmacéutica que comprende lacosamida y levetiracetam con efecto anticonvulsionante sinérgico
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
MX2009004233A (es) * 2006-10-18 2009-08-12 Pfizer Prod Inc Compuestos de biaril eter urea.
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2008132139A2 (en) * 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
US20090082422A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levetiracetam
MX2010009222A (es) * 2008-03-03 2010-09-28 Ucb Pharma Sa Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
US7741327B2 (en) * 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
WO2010002869A1 (en) * 2008-07-01 2010-01-07 Concert Pharmaceuticals, Inc. 2-oxo-1-pyrrolidine derivatives
EP2147911A1 (en) 2008-07-24 2010-01-27 ZaCh System S.p.A. Process for the preparation of levetiracetam
JP4644881B2 (ja) 2008-09-19 2011-03-09 高砂香料工業株式会社 ルテニウム錯体の製造方法
CA2740610C (en) 2008-10-16 2020-01-07 The Johns Hopkins University Synaptic vesicle protein 2a inhibitors for treating age-related cognitive impairment
WO2010048423A1 (en) * 2008-10-24 2010-04-29 Ark Diagnostics, Inc. Levetiracetam immunoassays
US8722715B2 (en) * 2008-11-07 2014-05-13 NovaBay Pharmaceuticals Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
KR101689688B1 (ko) * 2008-11-18 2016-12-26 유씨비 파마, 에스.에이. ２­옥소­１­피롤리딘 유도체를 포함하는 지연 방출형 제형
CA2741038C (en) * 2008-11-18 2015-01-13 Ucb Pharma S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
FR2939311A1 (fr) * 2008-12-08 2010-06-11 Oreal Utilisation d'un derive diester de pyrrolidinone 4-carboxy comme solvant dans les compositions cosmetiques ; compositions cosmetiques les contenant
US8563036B2 (en) 2009-02-09 2013-10-22 Ucb Pharma, S.A. Pharmaceutical compositions comprising Brivaracetam
US8846411B2 (en) * 2009-06-11 2014-09-30 Microgenics Corporation Derivatives, reagents, and immunoassay for detecting levetiracetam
US20120171125A1 (en) 2009-08-07 2012-07-05 Ucb Pharma, S.A. Methods for Enhancing the Cognitive Function
US7939676B2 (en) 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
US8487591B1 (en) 2009-12-31 2013-07-16 Cirrus Logic, Inc. Power control system with power drop out immunity and uncompromised startup time
IN2012DN02793A (es) * 2009-10-23 2015-07-24 Ucb Pharma Sa
PL389364A1 (pl) 2009-10-23 2011-04-26 Uniwersytet Jagielloński Nowe zastosowanie pochodnych 2-pirolidonu
US20110212928A1 (en) 2010-02-09 2011-09-01 The Johns Hopkins University Methods and compositions for improving cognitive function
FR2961101B1 (fr) 2010-06-09 2013-01-25 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee par un radical ester ou amide, et au moins un pigment ou un colorant direct pour la teinture des matieres keratiniques
FR2961099B1 (fr) 2010-06-09 2012-06-15 Oreal Derives de 2-pyrrolidone fonctionnalisee par un radical ester, acide ou amide, la composition cosmetique les comprenant et leur utilisation pour le conditionnement des matieres keratiniques
FR2961098A1 (fr) 2010-06-09 2011-12-16 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee en position 4 par un acide carboxylique ou amide, et au moins un colorant direct ou un pigment pour la teinture des fibres keratiniques
US8866452B1 (en) 2010-08-11 2014-10-21 Cirrus Logic, Inc. Variable minimum input voltage based switching in an electronic power control system
US9510401B1 (en) 2010-08-24 2016-11-29 Cirrus Logic, Inc. Reduced standby power in an electronic power control system
US8466297B2 (en) 2010-11-01 2013-06-18 Milan Soukup Manufacturing process for (S)-Pregabalin
BR112013012062B1 (pt) 2010-11-15 2020-06-02 Agenebio, Inc Composto derivado da piridazina ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso do composto
CA2826765C (en) * 2011-02-09 2021-04-06 The Johns Hopkins University Methods and compositions for improving cognitive function
HUE026889T2 (en) 2011-04-18 2016-07-28 Ucb Biopharma Sprl 2-Oxo-1-imidazolidinyl derivatives imidazotiadiazol
WO2012167127A1 (en) 2011-06-03 2012-12-06 Cirrus Logic, Inc. Control data determination from primary-side sensing of a secondary-side voltage in a switching power converter
CN103906745B (zh) 2011-09-30 2017-08-25 塔夫斯大学 用于治疗神经变性疾病的尿苷二磷酸衍生物、组合物和方法
JP6298766B2 (ja) * 2011-12-27 2018-03-20 バイオ−ファーム ソリューションズ カンパニー リミテッド てんかんの予防または治療に使用するためのフェニルカルバメート化合物
TW201408293A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
TW201408294A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除
CA2885369A1 (en) 2012-09-28 2014-04-03 Tufts University Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
PT2928865T (pt) 2012-12-07 2018-06-11 Merck Sharp & Dohme Processo de transaminação biocatalítica
WO2014087367A2 (en) * 2012-12-09 2014-06-12 Mahesh Kandula Compositions and methods for the treatment of neurological diseases and its associated complications
US9970929B2 (en) 2013-01-18 2018-05-15 Ark Diagnostics, Inc. Voriconazole immunoassays
EP2956444B1 (en) 2013-02-13 2018-05-30 ARK Diagnostics, Inc. Posaconazole immunoassays
AR095442A1 (es) 2013-03-13 2015-10-14 Univ Tufts Derivados de nucleósido de uridina, composiciones y métodos de uso
AU2014243707B2 (en) 2013-03-13 2018-08-30 Tufts University Uridine nucleoside derivatives, compositions and methods of use
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CN103342672B (zh) * 2013-07-02 2015-12-23 扬州大学 取代吡咯烷-2-酮的新合成方法
JP6465634B2 (ja) * 2013-12-05 2019-02-06 株式会社日本触媒 環状アミド基含有重合体
JP6453632B2 (ja) * 2013-12-05 2019-01-16 株式会社日本触媒 環状アミドアクリレート含有組成物およびその製造方法
JP6883988B2 (ja) 2013-12-20 2021-06-09 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
CN104098497B (zh) * 2014-06-17 2016-04-13 王庚禹 一种新的酰胺类化合物
WO2016075082A1 (en) 2014-11-10 2016-05-19 Sandoz Ag Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
EP3258921A1 (en) 2015-02-20 2017-12-27 UCB Biopharma SPRL Combination treatment
CN106365986B (zh) * 2015-07-21 2019-01-08 苏州鹏旭医药科技有限公司 化合物及其制备方法和在合成布瓦西坦中的用途
EP3302441B1 (en) * 2015-05-25 2023-12-13 Suzhou PengXu Pharmatech Co. Ltd Processes to produce brivaracetam
CN106279074B (zh) * 2015-05-25 2018-06-26 苏州鹏旭医药科技有限公司 一种化合物及其制备方法和在合成布瓦西坦中的用途
WO2016205739A1 (en) 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
RU2748992C2 (ru) 2015-06-19 2021-06-02 Центурион Байофарма Корпорейшн Системы доставки для контролируемого высвобождения лекарственного средства
WO2017076737A1 (en) 2015-11-03 2017-05-11 Ucb Biopharma Sprl Continuous process for preparing brivaracetam
US10421717B2 (en) 2015-11-03 2019-09-24 Ucb Biopharma Sprl Process for preparing brivaracetam
CN106748748B (zh) * 2015-11-10 2021-08-24 成都国为生物医药有限公司 一种布瓦西坦的制备方法及其中间体
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
CN105646319B (zh) * 2015-12-30 2018-05-18 佛山市隆信医药科技有限公司 一种布瓦西坦的制备方法
WO2017192665A1 (en) 2016-05-03 2017-11-09 The Regents Of The University Of California Inhibitors of ires-mediated protein synthesis
RU2629117C1 (ru) * 2016-06-14 2017-08-24 Сизов Владимир Владимирович Способ получения 4-замещенного 2-[2-оксо-1-пирролидинил] ацетамида
CN107513031B (zh) * 2016-06-16 2022-08-02 上海医药集团股份有限公司 一种2-氧代-1-吡咯烷手性衍生物的制备方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
AU2018210393A1 (en) 2017-01-20 2019-07-25 The Regents Of The University Of California Inhibitors of the N-terminal domain of the androgen receptor
WO2018141276A1 (zh) * 2017-02-05 2018-08-09 苏州鹏旭医药科技有限公司 布瓦西坦中间体的晶型a及其制备方法和布瓦西坦的晶型c及其制备方法
CN106866483A (zh) * 2017-02-05 2017-06-20 苏州鹏旭医药科技有限公司 布瓦西坦的晶型c及其制备方法
CN108503610B (zh) 2017-02-24 2019-09-13 北京艾百诺医药股份有限公司 一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
CN108658831B (zh) * 2017-03-30 2021-11-05 江苏豪森药业集团有限公司 2-氧代-1-吡咯烷衍生物或其盐的制备方法
EP3615513B1 (en) 2017-04-24 2022-07-20 Tesaro, Inc. Methods of manufacturing of niraparib
CN107793342A (zh) * 2017-10-19 2018-03-13 丽珠集团新北江制药股份有限公司 一种布瓦西坦的制备方法
CN107721896A (zh) * 2017-10-19 2018-02-23 丽珠集团新北江制药股份有限公司 一种布瓦西坦的中间体的制备方法
EP4344747A2 (en) 2017-11-30 2024-04-03 LadRx Corporation Albumin-binding prodrugs of auristatin e derivatives
US11572373B2 (en) 2017-11-30 2023-02-07 Ladrx Corporation Maytansinoid-based drug delivery systems
CN108147988B (zh) * 2018-02-13 2020-10-02 扬州奥锐特药业有限公司 一种高手性纯度内酰胺化合物的制备方法
CN108530402B (zh) * 2018-04-10 2020-06-26 浙江工业大学 一种(R)-3-丙基-γ-丁内酯的制备方法
EP3566760A1 (en) * 2018-05-07 2019-11-13 Universite Libre De Bruxelles Method for nucleating crystals from a solution in a capillary tube
MX2020011170A (es) 2018-05-08 2020-11-12 UCB Biopharma SRL Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona.
BR112020026062B1 (pt) 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
CN110615744B (zh) 2018-06-20 2023-01-06 上海朴颐化学科技有限公司 一种布瓦西坦中间体及其制备方法
EP3813841A4 (en) 2018-06-29 2022-03-09 The Regents Of The University Of California NEW MOLECULAR FORCEPS AGAINST NEUROLOGICAL DISORDERS AND VIRAL INFECTION
RU2699669C1 (ru) * 2018-07-04 2019-09-09 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые составы N-карбамоилметил-4-фенил-2-пирролидона
MX2021000895A (es) 2018-07-27 2021-08-24 California Inst Of Techn Inhibidores de cinasas dependientes de ciclinas (cdk) y usos de los mismos.
US11214568B2 (en) 2018-10-18 2022-01-04 California Institute Of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
EP3890833B1 (en) 2018-12-04 2023-06-07 Metys Pharmaceuticals AG Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio
CN109932442A (zh) * 2019-03-04 2019-06-25 成都美域高制药有限公司 一种布瓦西坦异构体的检测方法
CA3134779A1 (en) 2019-03-25 2020-10-01 California Institute Of Technology Prmt5 inhibitors and uses thereof
KR20220016918A (ko) 2019-06-04 2022-02-10 하거 바이오사이언시즈, 엘엘씨 오렉신 길항제로서의 이미다졸로 유도체, 조성물 및 방법
CN110357752A (zh) * 2019-08-15 2019-10-22 中国工程物理研究院化工材料研究所 一种快速制备均匀包覆含能材料的方法
RU2732245C1 (ru) * 2019-08-30 2020-09-14 Ооо "Валента-Интеллект" Новые составы n-карбамоилметил-4-фенил-2-пирролидона для лечения и профилактики ожирения
CN110551050A (zh) * 2019-09-02 2019-12-10 南通大学 一种2-[3’-(N-Boc-吡咯基)]-苯甲酸的合成方法
US10781170B1 (en) 2019-10-21 2020-09-22 Divi's Laboratories Ltd. Process for preparing Brivaracetam
US20230100559A1 (en) 2020-01-07 2023-03-30 The Trustees Of Princeton University Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism
WO2021216781A1 (en) 2020-04-21 2021-10-28 President And Fellows Of Harvard College Afmt analogs and their use in methods of treating parkinson's disease
LV15614A (lv) 2020-07-30 2022-02-20 Latvijas Organiskās Sintēzes Institūts 2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi
WO2022035805A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
AU2021326457A1 (en) 2020-08-10 2023-03-16 Dana-Farber Cancer Institute, Inc. Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
AU2021324967A1 (en) 2020-08-10 2023-03-16 Dana-Farber Cancer Institute, Inc. Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
CN116323571A (zh) 2020-10-23 2023-06-23 丹娜法伯癌症研究院 肌酸激酶（ck）的共价抑制剂以及其用于治疗和预防癌症的用途
WO2022133237A2 (en) 2020-12-18 2022-06-23 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
US11571481B2 (en) 2020-12-21 2023-02-07 Cornell University Peptide-linked drug delivery system
WO2022150574A1 (en) 2021-01-08 2022-07-14 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
US11400074B1 (en) 2021-02-01 2022-08-02 Divi's Laboratories Ltd. Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
CN114948953A (zh) * 2021-06-29 2022-08-30 四川大学华西医院 一种杂原子取代芳香类化合物及其盐的用途
CN113511994B (zh) * 2021-08-16 2023-03-21 江苏八巨药业有限公司 一种左乙拉西坦的制备方法
CN114634437B (zh) * 2022-03-29 2023-05-30 武汉氟本氘合新材料科技有限公司 一种布瓦西坦的简易制备方法
US11884623B2 (en) 2022-05-23 2024-01-30 Divi's Laboratories Ltd. Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam
WO2023250157A1 (en) 2022-06-24 2023-12-28 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
WO2024013209A1 (en) 2022-07-13 2024-01-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
WO2024049236A1 (ko) * 2022-08-31 2024-03-07 고려대학교 산학협력단 키랄 감마 락탐 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 제조방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD92031A (es) *
DE92031C (es)
US2836599A (en) * 1957-03-07 1958-05-27 Aerojet General Co Nu-(carboxyalkyl) dinitro lactams
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
US4008281A (en) 1973-12-03 1977-02-15 Monsanto Company Asymmetric catalysis
HU177239B (hu) 1974-10-15 1981-08-28 Monsanto Co Eljárás N-acetamido-L-alanin-származékok előállítására α-acetamido-akrilsav-származékok aszimmetrikus katalitikus hídrogénezésével
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
CN1015542B (zh) * 1984-05-15 1992-02-19 尤西比公司 (R)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法
JPS60166692A (ja) 1984-09-28 1985-08-29 Kazuo Achinami 新規不斉還元試薬
CH666891A5 (de) * 1985-11-26 1988-08-31 Lonza Ag 4-alkoxy-2-oxo-pyrrolidin-1-yl-essigsaeure-c(1)-c(4)-alkylester, deren herstellung und verwendung.
DE3719873A1 (de) * 1987-06-13 1988-12-29 Basf Ag Verfahren zur herstellung von itaconsaeurediestern und itaconsaeure
JPH0757758B2 (ja) 1988-10-24 1995-06-21 高砂香料工業株式会社 ルテニウム―ホスフィン錯体
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
CA2067614C (en) * 1991-05-02 2002-07-30 Eiichi Otomo Agent for improving dementia
US5171892A (en) 1991-07-02 1992-12-15 E. I. Du Pont De Nemours And Company Chiral phospholanes via chiral 1,4-diol cyclic sulfates
GB9319732D0 (en) 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
JPH1180027A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
AR020115A1 (es) * 1998-08-06 2002-04-10 Daiichi Seiyaku Co Agente terapeutico o preventivo para epilepsias rebeldes y uso del compuesto para la produccion de los mismos
CZ20001055A3 (cs) * 1998-10-02 2000-08-16 Dupont Pharmaceuticals Company Nové laktamové inhibitory metaloproteázy
EP1600168A3 (en) 1999-12-01 2009-09-23 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same

Also Published As

Publication number Publication date
US20080097109A1 (en) 2008-04-24
CA2401033C (en) 2008-07-29
RO121597B1 (ro) 2007-12-28
NL300815I2 (es) 2016-07-27
AU2005200717B2 (en) 2007-05-17
JP2006022107A (ja) 2006-01-26
IL166768A (en) 2010-04-15
IS6481A (is) 2002-07-23
IL150842A0 (en) 2003-02-12
PL212197B1 (pl) 2012-08-31
ATE445597T1 (de) 2009-10-15
MY138966A (en) 2009-08-28
HUS1600017I1 (hu) 2020-02-28
LTPA2016013I1 (lt) 2016-05-25
US20040192757A1 (en) 2004-09-30
BE2016C012I2 (es) 2020-01-30
EP1452524A1 (en) 2004-09-01
PL210121B1 (pl) 2011-12-30
CN1404469A (zh) 2003-03-19
CA2401033A1 (en) 2001-08-30
PL359388A1 (en) 2004-08-23
ES2248307T3 (es) 2006-03-16
MXPA02008206A (es) 2004-04-05
CU23293B7 (es) 2008-06-30
HK1052695A1 (en) 2003-09-26
HK1052516A1 (en) 2003-09-19
HK1052695B (zh) 2005-05-06
MY140593A (en) 2009-12-31
CN1179944C (zh) 2004-12-15
ZA200205671B (en) 2003-11-10
US20050171187A1 (en) 2005-08-04
HUP0204526A2 (hu) 2003-04-28
DE60119397T2 (de) 2007-04-19
MY127149A (en) 2006-11-30
US20050159475A1 (en) 2005-07-21
IS7918A (is) 2005-06-29
EP1477478A3 (en) 2004-11-24
EP1452524B1 (en) 2009-10-14
NZ520448A (en) 2004-03-26
PT1447399E (pt) 2006-09-29
EP1577296A1 (en) 2005-09-21
SI1265862T1 (sl) 2006-02-28
AU2001252144B2 (en) 2005-04-28
US6806287B2 (en) 2004-10-19
WO2001062726A3 (en) 2002-01-17
KR100720784B1 (ko) 2007-05-23
DE60107216T2 (de) 2005-11-03
LU92993I2 (fr) 2016-05-11
AU5214401A (en) 2001-09-03
IS7920A (is) 2005-06-29
DK1452524T3 (da) 2010-03-01
EG24375A (en) 2009-03-19
DE60113514D1 (de) 2005-10-27
NO20023997D0 (no) 2002-08-22
RU2291860C3 (ru) 2017-11-16
KR20020075926A (ko) 2002-10-07
US6858740B2 (en) 2005-02-22
HUP0204526A3 (en) 2005-03-29
DE60107216D1 (de) 2004-12-23
HU229514B1 (en) 2014-01-28
JP2006022108A (ja) 2006-01-26
CY2016022I2 (el) 2016-10-05
IS7923A (is) 2005-06-29
LTC1265862I2 (lt) 2023-09-11
CU23201A3 (es) 2007-04-06
YU63202A (sh) 2005-09-19
CY2016022I1 (el) 2016-10-05
CO5271667A1 (es) 2003-04-30
KR20050091112A (ko) 2005-09-14
AU2005200718B2 (en) 2007-05-24
YU63102A (sh) 2005-09-19
HU0500902D0 (en) 2005-12-28
IL150842A (en) 2008-06-05
ZA200205837B (en) 2003-11-04
IL150757A0 (en) 2003-02-12
AU2001252144C1 (en) 2008-03-20
BG107004A (bg) 2003-04-30
CY1109718T1 (el) 2014-08-13
CN1680314A (zh) 2005-10-12
NO20023995L (no) 2002-10-21
ES2231501T3 (es) 2005-05-16
IS7919A (is) 2005-06-29
EP1604979A1 (en) 2005-12-14
EP1447399B9 (en) 2006-10-18
IS2754B (is) 2011-09-15
KR20020075927A (ko) 2002-10-07
HUP0300196A2 (hu) 2003-06-28
IS2119B (is) 2006-06-15
EP1263727B1 (en) 2004-11-17
EP1447399B1 (en) 2006-05-03
MEP6109A (en) 2011-12-20
JP4081275B2 (ja) 2008-04-23
DE60119397D1 (de) 2006-06-08
EP1477478B1 (en) 2010-11-17
EP1265862B1 (en) 2005-09-21
JP4938259B2 (ja) 2012-05-23
DK1265862T3 (da) 2006-01-30
ATE304999T1 (de) 2005-10-15
CN1740150A (zh) 2006-03-01
ATE325093T1 (de) 2006-06-15
KR100759145B1 (ko) 2007-09-14
HUP0300196A3 (en) 2005-10-28
GB0004297D0 (en) 2000-04-12
RS50455B (sr) 2010-03-02
CZ304702B6 (cs) 2014-09-03
US7692028B2 (en) 2010-04-06
US20120035239A1 (en) 2012-02-09
SA01220078B1 (ar) 2006-10-29
IS7922A (is) 2005-06-29
NO324051B1 (no) 2007-08-06
JP4769756B2 (ja) 2011-09-07
ME00595B (me) 2011-12-20
ATE488500T1 (de) 2010-12-15
NO2016005I2 (no) 2016-03-08
US20040116507A1 (en) 2004-06-17
EP1265862A2 (en) 2002-12-18
BG65803B1 (bg) 2009-12-31
ATE282592T1 (de) 2004-12-15
US6911461B2 (en) 2005-06-28
US20030040631A1 (en) 2003-02-27
CN1404470A (zh) 2003-03-19
EP1477478A2 (en) 2004-11-17
DE60143493D1 (de) 2010-12-30
US8492416B2 (en) 2013-07-23
DE60140222D1 (de) 2009-11-26
US20030120080A1 (en) 2003-06-26
BG65783B1 (bg) 2009-11-30
JP2007182459A (ja) 2007-07-19
EP1577295A1 (en) 2005-09-21
CY1105517T1 (el) 2010-07-28
DK1447399T3 (da) 2006-08-28
TW200626545A (en) 2006-08-01
US20040087646A1 (en) 2004-05-06
NO20023995D0 (no) 2002-08-22
BR0108664A (pt) 2003-04-29
FR16C1001I1 (fr) 2016-07-01
US8034958B2 (en) 2011-10-11
AU2005200718A1 (en) 2005-03-17
ES2264060T3 (es) 2006-12-16
RU2292336C2 (ru) 2007-01-27
AU778510B2 (en) 2004-12-09
EP1447399A1 (en) 2004-08-18
JP2003523996A (ja) 2003-08-12
NO20053645L (no) 2002-10-22
IS6472A (is) 2002-07-16
NO2016005I1 (no) 2016-03-08
RU2291860C2 (ru) 2007-01-20
NO324485B1 (no) 2007-10-29
CZ20022849A3 (cs) 2003-02-12
WO2001062726A2 (en) 2001-08-30
RU2002124865A (ru) 2004-01-10
SA01220027B1 (ar) 2006-09-19
MY139420A (en) 2009-09-30
DE60113514T2 (de) 2006-05-18
PL365159A1 (en) 2004-12-27
BRPI0108664B8 (pt) 2021-05-25
AU7389601A (en) 2001-09-12
CN1303066C (zh) 2007-03-07
IS7921A (is) 2005-06-29
US7358276B2 (en) 2008-04-15
JP2003528828A (ja) 2003-09-30
US20050171188A1 (en) 2005-08-04
RU2005125645A (ru) 2007-02-20
KR100681580B1 (ko) 2007-02-09
FR16C1001I2 (fr) 2017-02-03
US20100222576A1 (en) 2010-09-02
CZ20022850A3 (cs) 2003-02-12
IL170181A (en) 2010-11-30
CA2401048C (en) 2009-01-20
BR0108657A (pt) 2003-04-29
NO20053644L (no) 2002-10-22
KR20050090090A (ko) 2005-09-12
CN1740151A (zh) 2006-03-01
RU2355680C2 (ru) 2009-05-20
RU2006125756A (ru) 2008-01-27
ES2334998T3 (es) 2010-03-18
MXPA02008056A (es) 2004-08-12
CN1208319C (zh) 2005-06-29
TW200626544A (en) 2006-08-01
RU2005125569A (ru) 2007-02-20
HU230270B1 (hu) 2015-11-30
BG107016A (en) 2003-04-30
US6713635B2 (en) 2004-03-30
US20040092576A1 (en) 2004-05-13
US6784197B2 (en) 2004-08-31
US7217826B2 (en) 2007-05-15
PT1452524E (pt) 2010-01-18
EP1263727A1 (en) 2002-12-11
KR100816185B1 (ko) 2008-03-21
JP4121744B2 (ja) 2008-07-23
ES2355140T3 (es) 2011-03-23
PL213669B1 (pl) 2013-04-30
BRPI0108664B1 (pt) 2016-07-26
WO2001064637A1 (en) 2001-09-07
AU2005200717A1 (en) 2005-03-17
RO121559B1 (ro) 2007-11-30
IS2176B (is) 2006-12-15
CZ304420B6 (cs) 2014-04-30
IL166768A0 (en) 2006-01-15
US6969770B2 (en) 2005-11-29
BG109297A (en) 2006-06-30
RS50454B (sr) 2010-03-02
HK1052516B (zh) 2006-02-10
BG65923B1 (bg) 2010-05-31
NO20023997L (no) 2002-10-22
CA2401048A1 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
CO5280059A1 (es) Derivados de 2-ox-1-pirrolidina, procewo para prepararlos y sus aplicaciones
CO4990929A1 (es) Compuestos de difenilurea sustituidos con sulfonamidas como antagonistas de los receptores de il-8
CO5261497A1 (es) Gama-hidroxi-2-(fluoroalquilamino-carbonil)-1-piperazino pentanamidas y sus usos
CY1106087T1 (el) Παραγωγα τετραϋδροκινολινης
CY1108313T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
CO5150149A1 (es) Composiciones farmaceuticas derivadas de quinolina
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
CY1107509T1 (el) Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεων
CO5200848A1 (es) Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales
AR011101A1 (es) Compuesto derivado de acidos arilsulfonilaminohidroxiamicos y composicion farmaceutica que lo contiene
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
CY1108254T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
AR011623A1 (es) Compuestos de sulfonamidas, procedimiento para prepararlos y composiciones farmaceuticas para potenciar las funciones de los glutamatoreceptores enmamiferos.
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
CO5310550A1 (es) Nuevo derivado de androstano antiinflamatorio, su polimorfo, sus formas cristalinas solvatadas, composiciones farmaceutias, proceso para prepararlo, intermediario
PE20021088A1 (es) Amidas de acidos antranilicos, procedimiento para su preparacion asi como preparados farmaceuticos que las contienen
AR054369A1 (es) Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa
RS51047B (sr) Derivati 4-tetrazolil-4-fenilpiperidina za lečenje bola
CO5271675A1 (es) Derivados de decahidro-isoquinolinas, proceso para su preparacion, composicion y compuestos farmaceuticos que los contienen
AR012732A1 (es) Derivados de fenilquinolinas, procedimientos para su preparacion, composiciones farmaceuticas, y su uso para la fabricacion de medicamentos
CO5570675A2 (es) Compuestos sustituidos de benzimidazolo y su uso para el tratamiento del cancer
AR037940A1 (es) Compuestos antivirales de piridoquinoxalina
CO5200760A1 (es) Antagonistas del receptor de la il-8 ceptor il-8
IS2287B (is) Nýjar afleiður og hliðstæður af galantamíni

Legal Events

Date Code Title Description
FC Application refused